NCT05851677View on ClinicalTrials.gov

Disitamab Vedotin (RC48-ADC) in Breast Cancer

RecruitingOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

August 31, 2027

Conditions
Breast Cancer
Interventions
DRUG

Disitamab vedotin

recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks

Trial Locations (1)

200127

RECRUITING

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER